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FRETbeta-Amyloid (Aβ) is the primary protein component of senile plaques in Alzheimer's disease (AD) and is
believed to play a role in its pathology. To date, the mechanism of action of Aβ in AD is unclear. We and others
have observed that Aβ interacts either with or in the vicinity of the α6 sub-unit of integrin, and believe this
may be important in its interaction with neuronal cells. In this study, we used confocal microscopy and ﬂow
cytometry to explore the residue speciﬁc interactions of Aβ40 with the cell surface and the α6 integrin receptor
sub-unit.Weprobed the importance of the RHD sequence inAβ40 and found that removal of the residues or their
mutation using theAβ8-40 or theD7N early onset AD sequence, respectively, led to a greater interaction between
Aβ40 and an antibody bound to theα6-integrin sub-unit, asmeasured byﬂuorescence resonance energy transfer
(FRET). These results suggest that the RHD sequence of Aβ40 does not mediate Aβ–α6 integrin interactions.
However, the cyclic RGDmimicking peptide, Cilengitide, reduced themeasured interaction between Aβ40 ﬁbrils
without the RHD sequence and an antibody bound to the α6-integrin sub-unit. We further probed the role of
electrostatic forces on Aβ40–cell interactions and observed that the Aβ sequence that included the N-terminal
segment of the peptide had reduced cellular binding at low salt concentrations, suggesting that its ﬁrst 7 residues
contribute to an electrostatic repulsion for the cell surface. These ﬁndings contribute to our understanding of Aβ–
cell surface interactions and may provide insight into development of novel strategies to block Aβ–cell interac-
tions that contribute to pathology in Alzheimer's disease.
Published by Elsevier B.V.1. Introduction
The β-amyloid (Aβ) peptide is a major protein component of senile
plaques found in the brains of Alzheimer’s disease patients (AD) [1]. Aβ
was ﬁrst sequenced nearly 20 years ago and has long been believed to
play a role in the pathology of AD, however, the mechanism by which
it contributes to AD pathology is still under investigation [2,3]. At this
time, there is no consensus about themechanism bywhich Aβ interacts
with cells, whether or not certain interactions are speciﬁc or non-
speciﬁc, and if all modes of Aβ binding/interaction with the cell lead
to some biological response. Careful probing of the Aβ–cell interaction
is a ﬁrst step in understanding how Aβ leads to memory loss in
Alzheimer’s disease.
There have been reports ofmany different receptors involved in Aβ–
cell attachment and interactions associated with Aβ biological activity
and toxicity. Monomeric and ﬁbrillar Aβ has been found to bind scaven-
ger receptor classes A and B1 [4,5], the serpin enzyme complex (SEC-R)
[6], the formyl peptide chemotactic receptor (FPR) [7,8], heparan sulfate
proteoglycans [9,10], the insulin receptor and α5β1–integrin [11].Then, 4201 Wilson Blvd, Suite 665,
. Good).receptor for advanced glycation end products (RAGE) was found to be
to a possible cell surface receptor for Aβ42 ﬁbrils [12].The toxic effects
of Aβ have been reported to be mediated through interaction with
α7-type nicotinic acetylcholine receptors (nAChR) [13] and certain
Ca2+ permeable and impermeable receptors (NMDA and AMPA,
respectively) [14,15]. Aβ has also been reported to bind to the Ephrin
type-B receptor 2 (EphB2) [16], the amylin-3 receptor (AMY3) [17],
and the cellular prion protein (PrPC) [18,19]. In addition, APP (amyloid
precursor protein), the P75 neurotrophin receptor (P75NTR), the
CLAC-P/collagen type XXV (collagen-like Alzheimer amyloid plaque
component precursor/collagen XXV) and CD36-complex, involving
CD36, α6β1–integrin and CD47 have been reported to bind the ﬁbrillar
form of Aβ [20–23]. Finally, α1 integrins [24,25] and β1 integrins [11,
26] have been implicated in Aβ–cell membrane interactions linked
with AD.
There have also been numerous reports that Aβ interacts with cells
through a non-speciﬁc, non-receptor mediated mechanism [27–30].
Electrostatic interactions have been implicated in Aβ binding to speciﬁc
cell membrane components (negatively charged phospholipids and
gangliosides) [31,32], and also in Aβ toxicity [33]. Hence, Aβ binding
to the cell and its subsequent toxicity are possibly mediated through
nonspeciﬁc physicochemical interaction as well as speciﬁc binding
with receptors on cell membranes.
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cells is not just where on the cell that the peptide binds and how, but
alsowhich residues on the Aβ peptide are important for this interaction.
Residues Y10, K28 and H13 and H14 have been implicated in stabilizing
the Aβ membrane interaction, providing an electrostatic attraction
with the negatively charged cell membrane, and in the stabilization of
a membrane spanning pore, respectively [34–36]. In our laboratory,
we have found that the residues in the vicinity of K28 and N27 and
V36-V40 have been implicated in Aβ40 ﬁbril–cell interactions via com-
putational docking methods [37] and in vitro veriﬁcation [Keshet,
Peshesk 2014 in preparation]. Residues 1–16 have been shown to give
rise to the unique structural difference between aggregated species via
hydrogen exchange methods [38]. Other residues associated with
mutations linked to early-onset AD, such as the D7N (Tottori-Japanese)
mutation [39], may be important in Aβ cell interactions, however, their
signiﬁcance is not yet known.
We and others have shown that Aβ interacts with or near the α6
subunit of integrin receptor, in model cell lines, neurons, and glia [40,
41]. Others have shown how this interaction may be important in sig-
naling associated with NMDA- R and could have implications for learn-
ing and memory in AD [42]. Understanding the mechanism of Aβ–
integrin interactions is a ﬁrst step in designing new molecules that
block the interaction and potentially attenuate the Aβ–integrin associat-
ed signaling events that contribute to Aβ neurotoxicity [43,44].
We used this background as a basis to explore the residues on Aβ
that are important in Aβ–integrin interactions. We set out to examine
if Aβ40 ﬁbrils interacted with the integrin through the RHD sequence
(an integrin-afﬁnity binding sequence), and found not only that the
speciﬁc sequence did not contribute to Aβ–cell interactions, but that
electrostatic interactions at the N-terminal region instead may be
important in Aβ –cell interactions.
2. Materials and methods
2.1. Materials
All chemicals were purchased from Fisher (Pittsburgh, PA) or Sigma
Aldrich (St. Louis, MO), unless otherwise speciﬁed. Cell culture reagents
were obtained from Invitrogen (Carlsbad, CA). Primary antibodies for
Integrin subunits: Integrinα6 (C-18) goat polyclonal antibody, Integrin
α1 Antibody (R-19) goat polyclonal IgG antibody, Integrin β1 Antibody
(N-20) goat polyclonal antibody and their secondary antibody probe
Donkey anti-goats IgG–FITC antibody were purchased from Santa Cruz
Biotechnologies. All Aβ peptides (Aβ40, N-terminus Carboxytetra-
methylrhodamine (TAMRA) labeled-Aβ40, Aβ 8-40, D7N-Aβ40 and
G33L-Aβ) were purchased from AnaSpec (San Jose, CA).
2.2. Aβ ﬁbril preparation
Aβ40 stock was prepared by ﬁrst completely dissolving the peptide
in hexaﬂuoroisopropanol (HFIP) (5 mg/mL), aliquoting sufﬁcient
peptide for individual experiments into small tubes, then evaporating
off HFIP under vacuum until dry. Aβ40 ﬁlms prepared this way were
then stored at−80 °C until use. Aβ40 stock solutions were prepared
by dissolving Aβ40 at 10 mg/ml in ddH2O with 0.1% Triﬂuoroacetic
acid (TFA) for 45–60 min. The stock was diluted in PBS (138 mM NaCl,
10mMNa2HPO4, 2.7mMKCl, and 1.8mMKH2PO4) to a ﬁnal concentra-
tion of 100 μM, and was gently mixed using a rotator for 24 h at 37 °C.
Analogous methods were used to prepare ﬁbrils from Aβmutants.
2.2.1. Carboxytetramethylrhodamine (TAMRA) labeled-Aβ preparation
To prepare ﬂuorescently labeled Aβ ﬁbrils for use in ﬂuorescence
resonance energy transfer and binding experiments, 1% by mass
N-terminally labeled TAMRA-Aβ40 was incorporated into ﬁbrils. A
stock solution of 10 mg/mL TAMRA labeled Aβ, dissolved in DMSO,
was thawed from storage at −80 °C. TAMRA-Aβ in DMSO was thenadded to unlabeled Aβ (wild type ormutants) that was freshly dissolved
in 0.1% (v/v) TFA as prepared above, such that 1% of Aβ40 contained the
N-terminal TAMRA label. The resulting solutionwas diluted to 100 μM in
PBS and gently mixed for 24 h to form Aβ40 ﬁbrils that are uniformly
labeled and bound with the TAMRA-Aβmixed in with the preparation.
2.3. Cell culture
SH-SY5Y cells were purchased fromATCC (Manassas, VA, USA). Cells
were maintained in a humidiﬁed incubator with 5% CO2 at 37 °C in
Minimal Essential medium supplemented with 10% fetal bovine serum
(Invitrogen), 2% Penicillin–Streptomycin and 2% Fungizone.
Prior to each experiment, 50,000 or 100,000 cells per well were
seeded in a 96-well plate and were allowed to adhere to wells for
24 h. When needed, cells were differentiated for 72 h by removal of
Minimal Essential Media (MEM) and replacement with Neurobasal
serum free medium (Neurobasal ATM medium, 3 mM L-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin, and 4 mM B-27).
2.4. Fluorescence resonance energy transfer (FRET)
A series of FRET experiments was performed in which we examined
energy transfer between a TAMRA chromophore attached to the N
terminus of Aβ40 ﬁbrils and an FITC chromophore attached to a second-
ary antibody, which was bound to a primary antibody bound to the α6
subunit, the α1 subunit, or the β1 subunit of the integrin receptor as a
function of different modiﬁcation or mutations in the Aβ40 ﬁbril.
We take energy transfer as a measure of binding and/or proximity
of binding of Aβ to the integrin receptor subunit. For the pair of
ﬂuorophores uses in this study, we would expect to see a 50% energy
transfer if the two ﬂuorophores are within the Förster radius (R0) of
the donor and acceptor ﬂuorophore pair (Fluorescein isothiocyanate
and Tetramethylrhodamine) or in this case 55 A°. In our experiments,
since our donor and acceptor ﬂuorophores are on the N-terminus of
the Aβ peptide and a secondary antibody bound to a primary antibody
bound to the α6/α1/β1 subunit of the integrin receptor, we can only
probe for interactions in the vicinity of these integrin receptors, which
could be many receptors in a focal adhesion, or even an integrin con-
taining lipid raft.
2.4.1. FRET procedure
For the FRET experiments, SY5Y cells were plated at a density of
10,000 cells per well in cover plate wells (Nalge Nunc International/
Thermo Fisher (Pittsburgh, PA, USA)). The cells were fed with MEM
which was then replaced with serum free Neurobasal media to induce
differentiation for 72 h prior to imaging. The cells were ﬁxed with 4%
paraformaldehyde for 15 min, and then blocked with 2% bovine serum
albumin (BSA) buffer. Aggregated and labeled Aβ at 100 μM was then
added to each well, such that it covered the surface completely and
was then incubated for 2 h at 37 °C. The unbound Aβ was removed by
careful rinsing of the wells, following which the cells were labeled
with primary antibody speciﬁc for the subunit of integrin (1:50 for
3 h) and secondary antibody labeled with FITC (1:500 for 1 h at room
temp or overnight at 4°). They were further labeled with 5 μL DAPI
(380 nM in PBS, stains the nucleus exclusively) after permeabilization
with 0.4% Triton X100 buffer. The wells were mounted with drops of
mounting media and allowed to dry to prepare the slides for FRET
imaging.
We examined the transfer between ﬂuorescently labeled Aβ ﬁbrils
(Aβ 1–40, 8–40, N27P, G33L and D7N mutants) and the ﬂuorophore
attached to the secondary antibody associated with the speciﬁc subunit
of the integrin receptor using the Leica SP5 FRET wizard.
Cells were viewed through a Leica SP5 confocal microscope at
63,000× magniﬁcation and regions of interest (ROI) were identiﬁed
that had both donor (secondary antibody-FITC) and acceptor (Aβ-
TAMRA) labeling. Approximately 100 regions of interest (ROIs) were
2570 A. Venkatasubramaniam et al. / Biochimica et Biophysica Acta 1838 (2014) 2568–2577identiﬁed per sample. FRET was measured in the ROIs by measuring
the initial donor ﬂuorescence, then photo bleaching the receptor by
increasing acceptor laser intensity to 70% and bleaching 15 frames per
sample, and then measuring the donor ﬂuorescence after photo
bleaching. If energy transfer was occurring due to the proximity of
the two ﬂuorophores, then donor ﬂuorescence would increase upon
acceptor photo bleaching.
Efﬁciency of energy transfer was calculated using a function embed-
ded in the FRET Acceptor bleaching (AB)wizard in Leica LAS software as
follows:
FRETeff ¼
Dpost−Dpre
Dpost
 
;
where Dpost refers to the donor ﬂuorescence intensity post acceptor
bleaching and Dpre refers to the donor ﬂuorescence intensity prior to
acceptor bleaching.
The FRET values are then represented as box plots, with the box
being an interquartile range, the median value represented as a line
inside the box and the bottom section of the box representing data
falling between the 25th and 50th percentile of the data, while the top
section represents the data falling in the 50th to 75th percentile of the
data (if the FRET scores were ranked by numerical value). Outliers are
represented as asterisks and the lines or whiskers from the box bars
represent the spread of the data (minimum to maximum).
The circle with a cross inside the box is themean of the sample data.
FRETeff measurements were rejected if donor or acceptor pixel intensity
values were below 5 or above 255 (near the minimum or maximum
values possible in the measurement system). FRETeff values, where the
acceptor was not photo bleached were also rejected and not included
in the representation of the data. Statistical analysis of the data was per-
formed by using the Mann–Whitney test for the FRET efﬁciency values
of each sample versus control. The box plots and Mann–Whitney test
were chosen as the means of result representation and statisticalFig. 1. Representative confocal images of differentiated SH-SY5Y cells (60,000×) for FRET imag
blue in color. (b)α6–integrin subunit ﬂuoresces as green in this image and is labeled with Fluor
show up as red in this image. (d) Nucleus, integrin and Aβ ﬂuorescent stains overlaid in a single
(f) depict representative the regions of interest selected for FITC and TAMRA ﬂuorescence captanalysis because FRETeff and Aβ–cell binding data were found to be
typically non-normally distributed.
2.5. TEM imaging
Structures of the various aggregated peptides were captured by
using Transmission Electron Microscope (TEM) Imaging. Unlabeled
Aβ40 wild type and mutant peptides were aggregated as described
above. 10 μl of samples was dropped gently on the carbon coated
Formvar grids, 200 mesh (TedPella, Redding, CA) for 3 min, and then
washed in ddH2O for 10 s, after which 10 μl solution of 1% Uranyl ace-
tate in ddH2O was dropped on the grids for 2 min. Grids were viewed
using a Zeiss-1OCA microscope (Zeiss, Germany) equipped with an
Olympus Morada (Melville, NY) digital camera, using an accelerating
voltage of 60 kV. Images were taken at the Keith R Porter Imaging
Facility at UMBC. Images were taken randomly throughout grids, such
that individual ﬁbrils could be clearly visualized and at magniﬁcations
of up to ×160,000. Three images were captured per type of Aβ
sequence.
2.6. Aβ–cell binding assay
SH-SY5Y cells were seeded at 100,000 cells per well for binding
assays. Cells were adhered to the well over the course of 24 h, after
which, the cells were ﬁxed for 30 min with 4% paraformaldehyde (4%
PFM) in PBS in order to minimize cell loss during Aβ40 incubation.
The PFM was then removed and cells were washed thrice with PBS.
TAMRA labeled Aβ40 ﬁbrils (wild type or mutations/deletions) were
added to SH-SY5Y such that the ﬁnal concentration in the well was
50 μM, based on initial unlabeled Aβmonomer concentration. Aβ ﬁbrils,
and cells were incubated for 2 h at 37 °C, after which excess Aβ was
washed awaywith PBS; and cells were detached fromwells bymechan-
ical scraping.ing: (a) Nucleus of the cell stained with DAPI, a nuclei speciﬁc ﬂuorescent stain, depicted
escein Isothiocyanate (FITC) . (c) TAMRA-labeled ﬂuorescent beta-amyloid 40 (WT) ﬁbrils
frame alongwith the brightﬁeld image frame and captured as a single overlay image. (e) &
ured as images, and upon which acceptor bleaching is performed.
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logical, ﬂuorescently labeled Aβ ﬁbrils were prepared as above,
but then centrifuged at 13,000 rpm, 20 min, to separate ﬁbrils from
PBS buffer in which ﬁbrils were prepared. The ﬁbrils were then re-
suspended in 10 mM phosphate buffer with desired amounts of NaCl
and pH adjusted to the desired level. Subsequent washing prior to
ﬂow cytometry was done with the same buffer as used to resuspend
ﬁbrils. Phosphate bufferswith pH of 2, 3, 7.4, 9 and 12, andNaCl concen-
trations of 0.02 M, 0.2 M, 0.4 M and 0.56 M were used in these set of
experiments.
Cell associated ﬂuorescence intensity, indicative of Aβ ﬁbril bound
to cells, was detected using a BD FACS Array (San Diego, CA) ﬂow
cytometer. Cell samples were excited with a 635 nm laser and cell
associated ﬂuorescence emission was collected using the red ﬁlter
(653–669 nm). Themedian ﬂuorescence intensity of the cell population
was taken as a measure of the amount of Aβ bound to cell surface. Fluo-
rescence intensity measurements were corrected for the auto ﬂuores-
cence of unlabeled cells. Care was taken to ensure that free ﬁbrils that
might have been counted in the ﬂow cytometer were gated such that
they were not included in the Aβ ﬁbril–cell ﬂuorescence.
3. Results and discussion
As a step in the development of agents that will block Aβ–cell inter-
actions and thereby attenuate Aβ toxicity, we and others have probed
receptors on the cell surface associated for Aβ–cell interactions
[41,45–48] and residues on the Aβ ﬁbril or oligomer responsible for
the Aβ–cell interaction [49–52].To that end we have explored Aβ-
interactions with cholesterol [45], sialic acid [53,54], and phospholipids
[55] associated with the cell membrane, as well as speciﬁc interactionsa
b
Fig. 2. FRETeff between various Aβ peptides in aggregated form labeledwith TAMRA (Acceptor ﬂ
whisker plot representation, with the box being an interquartile range, the median value repre
50th percentile, the top part of the box representing data in the 50th to 75th percentile of the
asterisks and the lines or whiskers from the box bars represent the spread of the data (minim
Mann–Whitney test between each sample and control (WT-Aβ) is used for statistical analysis
and more dramatically depicts the larger subset population for 8-40 and Tottori Japan (D7N) A
8-40, horizontally angled and lined bar represents N27P Aβ, white bar Leu33 (G33L) Aβ, and twith certain receptors and signaling molecules [46,56], and identiﬁed
speciﬁc Aβ residues (K28) [50,56] or sequences (1–16, residues near
the C terminus) [41,50] as potential loci on the Aβ ﬁbril or oligomer
surface that participate in the Aβ–cell interactions.
We and others have shown that Aβ binds to or in the vicinity of an
integrin receptor [40,57,58]. We hypothesized that this interaction
may be mediated through the RHD sequence on the N-terminus of the
Aβ40 ﬁbril, a putative integrin binding sequence [41], and a part of the
Aβ peptide which is normally assumed to be unstructured and solvent
accessible even when Aβ is in ﬁbril form [59]. We supposed that by
elucidating the Aβ residues involved in this interaction, we might be
able to develop new targets to block Aβ associated biological activity
mediated through the integrin interaction.
To that end, a series of FRET experiments was performed in which
we examined energy transfer between Aβ40 ﬁbrils and an antibody
bound to speciﬁc subunits (α6,α1 and β1) of the integrin receptor as
a function of different modiﬁcation or mutations in the Aβ40 ﬁbril.
Since we did not label the integrin subunits directly, but rather used a
pair of primary and secondary antibodies to probe for regions of interest
on the cell surface, we can only conclude that Aβ bound near speciﬁc
subunits. We used SY5Y cells as our model system in these studies as
we and others have used them before to explore Aβ–cell interactions
in vitro [60–62]. SH-SY5Y cells have been shown to express α1, α3,
and β1 integrin subunits, as well as lower concentrations of α2, α4,
α5, α6, and αv, integrin subunits both when undifferentiated and
differentiated, though differentiation was found to increase expression
of integrin receptor subunits [63–66]. In earlier work, we have used
FRET to show that Aβ binds in the vicinity of the α6 subunit [Ramos,
VenkatasubramaniamandGood, submitted].We include theβ1 subunit
because of its role in binding to the RGD sequence [67] and its potentialurophore), andα6–integrin subunit labeledwith FITC (Donor ﬂuorophore). (a) A Box and
sented as a line inside the box, the bottom part of the box representing data in the 25th to
data if they are ranked numerically by their the FRET values. Outliers are represented as
um to maximum). The circle with a cross inside the box is the mean of the sample data.
(n = 200). (b) A frequency plot depict the various FRETeff value ranges for each peptide
βwith FRETeff of greater than 30%. Black bars represent WT Aβ, dark grey bars represent
he dotted bar represents Tottori-Japan (D7N).
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dance on the cell surface, and because it has not to our knowledge
been implicated in Alzheimer’s, making it an appropriate control.
Fig. 1 shows a group of representative confocal micrographs that
show the overlap of Aβ40 ﬁbril and α6 integrin staining, as well as
typical areas or regions of interest chosen for FRET measurements. In
Fig. 2, we show energy transfer between Aβ and the antibody bound
to theα6 integrin subunit for several Aβ ﬁbril sequenceswith andwith-
out the putative RHD integrin binding domain (residues 5 to 7 of the Aβ
sequence). We included in these experiments Aβ8-40, and Aβ40 D7N,
peptides with missing or mutated RHD sequences along with Aβ40
G33L and N27P, peptides with mutations in the β-turn region that we
did not anticipate being associated with integrin binding or peptide
aggregation. Fig. 2(a) shows box and whisker plots of the energy trans-
fer for all n (50 to 200) regions of interest measurements, where the
average (cross), median (line), 75% & 25% quartiles (end of the box
plots) and range of data (whiskers) are depicted.We chose this represen-
tation given that the data were not normally distributed. As can be seen
in Fig. 2a, signiﬁcantly greater energy transfer was seen between the
Aβ sequences without the RHD sequence (Aβ 8-40 and Aβ D7N) and
the antibody bound to the integrin subunit (p b 0.01) than sequences
with the RHD sequence. To further illustrate this point, we show the frac-
tion of the sample measurements taken with different observed FRET
ranges (Fig. 2b). As can been seen in Fig. 2b, almost 50% of the population
had measured FRET efﬁciencies of greater than 30% for Aβ8-40 and Aβ
D7N, while for all other Aβ sequences, a much smaller fraction of the
population had high FRET efﬁciencies.
We wanted to explore if the observed energy transfer and by exten-
sion the Aβ ﬁbril–cell surface binding, was speciﬁc for an integrin, evena
b
Fig. 3. FRETeff post exposure to cilengitide (RGDmimicking cyclic peptide, 5 μM, 24 h). (a) A bo
(WT-Aβwithout cilengitide) is used for statistical analysis (n= 50). (b) A frequency plot is use
the larger subset population forWT1-40, 8-40 and Tottori Japan (D7N) Aβwith FRETeff of less th
lined bar represents N27P Aβ, white bars Leu33 (G33L) Aβ, and the dotted bars represents Totthough the interaction did not appear to be mediated by the RHD
sequence on Aβ. Therefore we tried to block the interaction using the
cyclic RGD peptide, cilengitide that is known to inhibit certain integrin
receptors [68,69].
Cilengitide has been reported to inhibit integrin interactions when
applied in themicromolar range in vitro, and has reported high speciﬁc-
ity for αvβ3 and αvβ5 with activity against α5β1 [70,71]. Surprisingly
we found that cilengitide signiﬁcantly reduced energy transfer for the
two peptides that did not have the RHD sequence (Aβ 8-40 and Aβ40
D7N), as shown in Fig. 3(a) and (b). Without cilengitide, approximately
15% of the sampled regions of interest had the lowest levels of energy
transfer between the integrin subunit and wild type Aβ40, Aβ8-40
and Aβ D7N (Fig. 2b), while with cilengitide, 50% of population had
the lowest FRET levels with the same 3 Aβ sequences (wild type Aβ,
Aβ 8-40, and Aβ D7N; Fig. 3b). We also see that cilengitide enhanced
FRET between G33L Aβ and the antibody bound to the α6 integrin
receptor subunit (Fig. 3). This suggests that the cilengitide did not just
displace our antibody bound to the α6 integrin subunit, but instead
displaced some but not all Aβ ﬁbrils, depending upon their sequence.
One explanation for our observations that Aβ sequences without
the RHD sequence showed greater FRET efﬁciencies with the integrin
receptor subunit, but that a cyclic RGD peptide could block these same
peptides (but not all Aβ peptides) from interacting with the cell is
that the different Aβ sequence resulted in the formation of different
Aβ ﬁbril structures, which give rise to the differences in cell interaction
and energy transfer. To explore this hypothesis, we examined the struc-
ture of the Aβ peptides to ensure that all of the Aβ peptides used still
formedﬁbrils. TEM images of theAβﬁbrils are included in Supplementary
data (Fig. 1). No qualitative differences in macroscopic structure of thex and whisker plot representation. Mann–Whitney test between each sample and control
d to depict the various FRETeff value ranges for each peptide andmore dramatically depicts
an 30%. Black bars representWTAβ, dark grey bars represent 8-40, horizontally angled and
tori-Japan (D7N).
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reported that the Aβ D7N mutation leads to altered rates of ﬁbril elon-
gation [72,73], which should lead to differences in ﬁbril length but not
necessarily changes in ﬁbril structure relative to wild type Aβ40 ﬁbrils.
A second possibility is that the differences in observed energy trans-
fer with the different Aβ ﬁbrils resulted from differences in electrostatic
interactions of Aβ with the cell surface. There have been a number of
reports suggesting that electrostatic interactions are important in Aβ–
cell interactions and toxicity [74–77]. The cell surface is generally
regarded as negatively charged [78]. The ﬁrst 7 residues of the Aβ
sequence, DAEFRHD, contain 3 negatively charged amino acids under
physiological conditions. Removal of these ﬁrst 7 residues should
decrease potential electrostatic repulsion between the Aβ ﬁbril and
the cell surface. The D7N mutation would replace one negatively
charged amino acid with a neutral amino acid. To explore the potential
impact of electrostatic interactions on our results, we examined the
binding of Aβ-40 and Aβ 8-40 ﬁbrils to the cell surface as a function of
salt concentration and pH. These results are depicted in Fig. 4(a) and
(b), respectively. As can be seen in Fig. 4(a), as salt concentration
present during binding was increased, binding of Aβ 40 to the cell
increased, while binding of Aβ 8-40 decreased. As ionic strength (and
salt concentration) is increased, one would expect increased shielding
of charges such that electrostatic effects would diminish at higher salt
concentrations. Thus, we conclude that full length Aβ40 ﬁbrilsFig. 4. Binding assay to depict relative fraction of cells bound to Aβ, (a) across varying salt
concentrations (b) across varying pH. A box andwhisker plot representation,with the box
being an interquartile range, themedian value represented as a line inside the box and the
box ends representing the 25th and 75th quartile values of the data. Outliers are
represented as asterisks and the lines or whiskers from the box bars represent the spread
of the data (minimum to maximum). The circle with a cross inside the box is the mean of
the sample data.experiences electrostatic repulsion while Aβ8-40 ﬁbrils experienced
electrostatic attractionwith the cell surface. The greater change in bind-
ing to the cell surface at the different salt concentrations observed for
the Aβ8-40 ﬁbril compared to the full length Aβ40 ﬁbril suggests that
there are more charges involved in the Aβ8-40–cell surface interaction.
To further probe the role of charges on the Aβ surface on Aβ–cell
binding, we examined the effects of changing pH. We expected that
above the pKa of the basic amino acid residues or below the pKa of
the acidic residues, wemight see changes in binding because of changes
in electrostatic interactions. As seen in Fig. 4(b), binding of the full
length Aβ40 ﬁbril to the cell surface decreased as the pH increased,
suggesting that as the peptide became more negatively charged (at
increasing pH), binding diminished. Binding of Aβ 8-40 was greatest
at physiological pH, and decreased as pH increased or decreased. This
result is more difﬁcult to interpret, but might suggest that changing
the balance of charges on the Aβ8-40 sequence or the cell surface
diminish the Aβ8-40 ﬁbril electrostatic interaction with the surface.
These experiments measured binding of Aβ to the entire cell surface,
and were not speciﬁc for binding at or near the integrin receptor
subunit, however, they may suggest mechanisms of attraction that
play a part in the more speciﬁc Aβ–integrin interactions.
Along these same lines, when we showed that cilengitide, the cyclic
RGD peptide, attenuated some Aβ–integrin interactions, we may not
have been speciﬁcally blocking the RHD binding site on the cell surface
as we proposed, but instead may have been altering some non-speciﬁc
interactions, especiallywhen using cilengitide at relatively high concen-
trations. Cilengitide has functional groups which could pick up both a
positive and negative charge depending upon the environment [79],
and as well as an aromatic ring that could contribute to hydrophobic
interactions [80].
A third possible explanation for our observations that Aβ sequences
without the RHD sequence show greater FRET efﬁciencies with the
integrin receptor subunit, but that a cyclic RGD peptide could block
these same peptides (but not all Aβ peptides) from interacting with
the cell is that Aβ interacts through sequences other than the RHD
sequence, and potentially with a receptor other than the integrin recep-
tor subunit. RGD is a recognition site which can be recognized by the
majority of β1–integrins, but not all integrin subunits. Aβ does not con-
tain any other canonical integrin receptor binding sites, but some of the
integrin binding sequences are unknown [81]. We used an antibody to
an α6–integrin subunit, which typically interacts with laminin via an
unknown sequence (but not RGD) [24].
Aβ40 may have been binding to something other than an integrin
when we observed energy transfer between the Aβ40 ﬁbril and the
antibody bound to the α6–integrin subunit. FRET efﬁciency is related
to the distance donor and acceptor ﬂuorophore, thus our results indi-
cate only that mutations in the Aβ sequence impact the distance been
the Aβ ﬁbril and a secondary antibody bound to an integrin receptor
subunit. The actual Aβ–cell interaction which is impacted by the muta-
tions and deletions in the N terminus may be with a molecule in the
vicinity of the α6–integrin receptor subunit. Aβ may be binding to
another molecule co-localized with the integrin receptor subunit,
including other integrin receptor subunits other than the α6 subunit,
other receptors found within a focal adhesion, and/or receptors found
within a lipid raft in which the integrin subunit is localized. We have
previously found that Aβ binds in cholesterol rich, sialic rich regions of
the cell surface [45], which, along with co-localization with an integrin
receptor could suggest that Aβ binds to a receptor within a lipid raft
on the cell surface.
To investigate if Aβ bound to other integrin receptor subunits, we
repeated our FRET experimentwithAβ and theβ1 subunit of the integrin
receptor,which has been implicated in the Aβ–α6 integrin subunit inter-
action [21], as well as other Aβ cell interactions [11,26], andwith Aβ and
theα1 subunit of the integrin receptor, which has not been implicated in
AD. We performed the experiments with the Aβ 40, Aβ 8-40, and Aβ
D7N ﬁbrils in the absence and presence of cilengitide. The results from
2574 A. Venkatasubramaniam et al. / Biochimica et Biophysica Acta 1838 (2014) 2568–2577these experiments are shown in Figs. 5 and 6.We found that the average
energy transfer between all Aβ sequences and either the β1 or α1
integrin receptor subunit was less than 10%, and no more than 5% of all
regions tested had energy transfers at greater than 30%. In an unrelated
study, wemeasured FRET efﬁciencies of 10% or less between Aβ40 ﬁbrils
and antibodies bound to GalC and the transferrin receptor, two receptors
thought to be irrelevant and abundant on the cell surface [Ramos,
Venkatasubramaniam and Good, submitted]. These results suggest that
Aβ does not bind near the α1 or β1 subunit, or that the antibody used
to ﬂuorescently label the receptor blocks the site of Aβ binding. The rel-
atively high energy transfer between Aβ and antibodies bound to theα6
integrin receptor subunit compared to the α1 and β1 receptor subunits
suggests that theα6 subunit marks a speciﬁc location on the cell surface
for Aβ interactions. We still cannot conclude that Aβ interacts directly
with theα6 subunit, but only that the peptide interacts with the vicinity
of some but not all integrin receptor subunits.
It is probable that Aβ interacts with the cell surface via both speciﬁc
and non-speciﬁc interactions. Speciﬁc Aβ–integrin interaction may
have functional consequences given the role of integrin in FAK/Src
activation, and cell cycle activation, and eventual cell death [26,82].a
b
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Fig. 5. FRETeff between various Aβ peptides in aggregated form labeled with TAMRA (Accepto
measured in the absence or presence of cilengitide (indicated as RGD in ﬁgure). Cilengitide,
plot representation. Mann–Whitney test between each sample versus WT-Aβ is used for stati
each peptide, depicting the larger subset of the population to have a FRETeff of less than 10%. B
light grey bars representWT Aβ and cilengitide, dotted bars 8-40 Aβ and cilengitide and whiteRGD containing peptide–integrin interactions are linked to increases
in N-methyl-D-aspartate receptor (NMDA-R) mediated synaptic trans-
mission [83] and long term potentiation [84,85]. Thus, Aβ–integrin
interactions could impair molecular processes associated with learning
and memory. Non-speciﬁc interactions including electrostatic interac-
tions also play a role in Aβ–cell surface binding.
In this work we show that that Aβ binds in the vicinity of the α6
subunit of the integrin receptor, and that the interaction is attenuated
in the presence of a cyclic RGD peptide. We show that the seven N
terminal residues on the Aβ sequence contribute to an electrostatic
repulsion with the cell surface, and that if those residues are deleted
or mutated, the Aβ–cell interaction is enhanced, as is the Aβ–integrin
interaction (or interaction with the receptor in the vicinity of the
integrin). While our results suggest that the ﬁrst 7 amino acids are not
central to the Aβ–integrin interaction, they play an important role in
non-speciﬁc electrostatic interactions. Being able to manipulate Aβ
electrostatic interactions may be an important avenue to modulate Aβ
neurotoxicity associated with Alzheimer’s disease.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2014.06.011.D7N & RGD8-40 & RGDWT & RGD
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Fig. 6. FRETeff between various Aβ peptides in aggregated form labeled with TAMRA (Acceptor ﬂurophore), and β1–integrin subunit labeled with FITC (Donor ﬂuorophore) FRET was
measured in the absence or presence of cilengitide (indicated as RGD in ﬁgure). Cilengitide, when present, was added at 5 μM prior to the addition of the Aβ. (a) A box and whisker
plot representation. Mann–Whitney test between each sample and WT-Aβ is used for statistical analysis (n = 50). (b) A frequency plot depicts the various FRETeff value ranges for
each peptide, with the larger subset of the population having FRETeff less than 10%. Black bars represent Wild type (WT) Aβ, dark grey bars 8-40 Aβ,slashed line bars D7N Aβ, light
grey bars representWT Aβ and cilengitide, dotted bars 8-40 Aβ and cilengitide and white bars are D7N Aβ and cilengitide.
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